Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Drug Metabolism & Disposition
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Drug Metabolism & Disposition

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit dmd on Facebook
  • Follow dmd on Twitter
  • Follow ASPET on LinkedIn
Research ArticleArticle

S-2-PENTYL-4-PENTYNOIC HYDROXAMIC ACID AND ITS METABOLITE S-2-PENTYL-4-PENTYNOIC ACID IN THE NMRI-EXENCEPHALY-MOUSE MODEL: PHARMACOKINETIC PROFILES, TERATOGENIC EFFECTS, AND HISTONE DEACETYLASE INHIBITION ABILITIES OF FURTHER VALPROIC ACID HYDROXAMATES AND AMIDES

Daniel Eikel, Katrin Hoffmann, Karolin Zoll, Alfonso Lampen and Heinz Nau
Drug Metabolism and Disposition April 2006, 34 (4) 612-620; DOI: https://doi.org/10.1124/dmd.105.008078
Daniel Eikel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Katrin Hoffmann
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Karolin Zoll
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alfonso Lampen
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Heinz Nau
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

Structure-activity relationship studies of valproic acid (VPA) derivatives have revealed a quantitative correlation between histone deacetylase (HDAC) inhibition and induction of neural tube defects (NTDs) in the NMRI-exencephaly-mouse model, but this correlation has been, so far, limited to congeners with a carboxylic acid function. Whereas the classical HDAC inhibitor trichostatin A is active only as a hydroxamate but not as a carboxylic acid, we found that neither VPA amides nor hydroxamates inhibit HDACs, but can cause NTDs; e.g., 2-pentyl-4-pentynoic hydroxamic acid with its S-enantiomer being the potent teratogen. We therefore investigated the hypothesis that hydroxamic acid derivatives of VPA might be metabolized in vivo and may possibly be pro-teratogenic, as had been shown for valpromide but not valproic hydroxamic acid. We developed two stereoselective quantification methods based on chiral derivatization of VPA hydroxamates with (1R,2S,5R)-(–)-menthylchloroformate and carboxylic acid derivatives with (S)-(–)-1-naphthylethylamine, followed by gas chromatography-nitrogen phosphor detector analysis of biological samples. We then determined the pharmacokinetic profiles of S-2-pentyl-4-pentynoic hydroxamic acid and of S-2-pentyl-4-pentynoic acid in mice. S-2-Pentyl-4-pentynoic hydroxamic acid was found to be extensively metabolized to the corresponding carboxylic acid without affecting the stereochemistry at position C2. Furthermore, the metabolite S-2-pentyl-4-pentynoic acid was found to be very stable in vivo, with an extended half-life of 4.2 h compared with that of VPA, 1.4 h. Comparison of the individual HDAC inhibition abilities of additional VPA amides and hydroxamates, as measured by cellular and enzymatic assays, led us to the conclusion that both classes of VPA derivatives can be pro-teratogenic.

Footnotes

  • We thank the Deutsche Forschungsgemeinschaft (Project DFG-NA 104/2-1), the European Research Training Network (Project RTN2-2001-00370), the European Commission (6th Framework Programme project: ReProTect), the Federal Ministry for Education and Research (BBF-Project 0313070D), and the Academy for Animal Health (ATF) for financial support.

  • Article, publication date, and citation information can be found at http://dmd.aspetjournals.org.

  • doi:10.1124/dmd.105.008078.

  • ABBREVIATIONS: VPA, valproic acid; HDAC, histone deacetylase; NMRI, Naval Medical Research Institute; TSA, trichostatin A; SAHA, suberoylanilinhydroxamic acid; VPA-HA, valproic hydroxamic acid; IC50(HDAC), inhibitor concentration with half-maximal HDAC enzyme activity; NPD, nitrogen phosphor detector; GC-MS, gas chromatography-mass spectrometry; ATR IR, attenuated total reflection infrared spectroscopy; LOQ, limit of quantification; LOD, limit of detection; ANOVA, analysis of variance; TBS, Tris-buffered saline; TBS-M, Tris-buffered saline buffer containing 3% nonfat dry milk; BBB, blood-brain barrier.

    • Received October 29, 2005.
    • Accepted January 6, 2006.
  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

 

DMD articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Drug Metabolism and Disposition: 34 (4)
Drug Metabolism and Disposition
Vol. 34, Issue 4
1 Apr 2006
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Back Matter (PDF)
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Drug Metabolism & Disposition article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
S-2-PENTYL-4-PENTYNOIC HYDROXAMIC ACID AND ITS METABOLITE S-2-PENTYL-4-PENTYNOIC ACID IN THE NMRI-EXENCEPHALY-MOUSE MODEL: PHARMACOKINETIC PROFILES, TERATOGENIC EFFECTS, AND HISTONE DEACETYLASE INHIBITION ABILITIES OF FURTHER VALPROIC ACID HYDROXAMATES A…
(Your Name) has forwarded a page to you from Drug Metabolism & Disposition
(Your Name) thought you would be interested in this article in Drug Metabolism & Disposition.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

S-2-PENTYL-4-PENTYNOIC HYDROXAMIC ACID AND ITS METABOLITE S-2-PENTYL-4-PENTYNOIC ACID IN THE NMRI-EXENCEPHALY-MOUSE MODEL: PHARMACOKINETIC PROFILES, TERATOGENIC EFFECTS, AND HISTONE DEACETYLASE INHIBITION ABILITIES OF FURTHER VALPROIC ACID HYDROXAMATES AND AMIDES

Daniel Eikel, Katrin Hoffmann, Karolin Zoll, Alfonso Lampen and Heinz Nau
Drug Metabolism and Disposition April 1, 2006, 34 (4) 612-620; DOI: https://doi.org/10.1124/dmd.105.008078

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleArticle

S-2-PENTYL-4-PENTYNOIC HYDROXAMIC ACID AND ITS METABOLITE S-2-PENTYL-4-PENTYNOIC ACID IN THE NMRI-EXENCEPHALY-MOUSE MODEL: PHARMACOKINETIC PROFILES, TERATOGENIC EFFECTS, AND HISTONE DEACETYLASE INHIBITION ABILITIES OF FURTHER VALPROIC ACID HYDROXAMATES AND AMIDES

Daniel Eikel, Katrin Hoffmann, Karolin Zoll, Alfonso Lampen and Heinz Nau
Drug Metabolism and Disposition April 1, 2006, 34 (4) 612-620; DOI: https://doi.org/10.1124/dmd.105.008078
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • A PBPK model for CBD in adults and children
  • Antibiotics Induce Changes in the Expression of Rat DPGs
  • Metabolism of Efavirenz by P450s and UGTs in the Brain
Show more Articles

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About DMD
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Journal of Pharmacology and Experimental Therapeutics
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-009X (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics